Vascular endothelial growth factor-C expression in human prostatic carcinoma and its relationship to lymph node metastasis - PubMed (original) (raw)

Vascular endothelial growth factor-C expression in human prostatic carcinoma and its relationship to lymph node metastasis

T Tsurusaki et al. Br J Cancer. 1999 Apr.

Free PMC article

Abstract

Lymph node dissemination is a major prognostic factor in human cancer. However, the molecular mechanisms underlying lymph node metastasis are poorly understood. Recently, vascular endothelial growth factor-C (VEGF-C) was identified as a ligand for VEGF receptor-3 (VEGFR-3/Flt-4) and the expression of VEGFR-3 was found to be highly restricted to the lymphatic endothelial cells. In this report, we investigated the expression of VEGF-C and VEGFR-3 in human prostatic carcinoma tissue by using in situ hybridization and immunohistochemical staining respectively. Expression of VEGF-C mRNA in prostatic carcinoma was significantly higher in lymph node-positive group than in lymph node-negative group. In addition, the number of VEGFR-3-positive vessels was increased in stroma surrounding VEGF-C-positive prostatic carcinoma cells. These results suggest that the expression of VEGF-C in prostatic carcinoma cells is implicated in the lymph node metastasis.

PubMed Disclaimer

Similar articles

• Expression of vascular endothelial growth factor receptor-3 by lymphatic endothelial cells is associated with lymph node metastasis in prostate cancer.
  Zeng Y, Opeskin K, Baldwin ME, Horvath LG, Achen MG, Stacker SA, Sutherland RL, Williams ED. Zeng Y, et al. Clin Cancer Res. 2004 Aug 1;10(15):5137-44. doi: 10.1158/1078-0432.CCR-03-0434. Clin Cancer Res. 2004. PMID: 15297417
• Expression of vascular endothelial growth factors A, B, C, and D and their relationships to lymph node status in lung adenocarcinoma.
  Niki T, Iba S, Tokunou M, Yamada T, Matsuno Y, Hirohashi S. Niki T, et al. Clin Cancer Res. 2000 Jun;6(6):2431-9. Clin Cancer Res. 2000. PMID: 10873096
• The short form of the alternatively spliced flt-4 but not its ligand vascular endothelial growth factor C is related to lymph node metastasis in human breast cancers.
  Gunningham SP, Currie MJ, Han C, Robinson BA, Scott PA, Harris AL, Fox SB. Gunningham SP, et al. Clin Cancer Res. 2000 Nov;6(11):4278-86. Clin Cancer Res. 2000. PMID: 11106244
• [Genetics of lymphedema: from Milroy's disease to cancer investigations].
  Quéré I, Coupé M, Soulier-Sotto V, Evrard-Bras M, Laroche JP, Janbon C. Quéré I, et al. Rev Med Interne. 2002 Jun;23 Suppl 3:379s-387s. doi: 10.1016/s0248-8663(02)80379-4. Rev Med Interne. 2002. PMID: 12162200 Review. French.
• Metastatic diversity in human prostatic carcinoma: implications of growth factors and growth factor receptors for the metastatic phenotype.
  Ware JL, Maygarden SJ. Ware JL, et al. Pathol Immunopathol Res. 1989;8(5-6):231-49. doi: 10.1159/000157154. Pathol Immunopathol Res. 1989. PMID: 2561207 Review. No abstract available.

Cited by

• Insulin-like growth factor family and prostate cancer: new insights and emerging opportunities.
  Elemam NM, Hotait HY, Saleh MA, El-Huneidi W, Talaat IM. Elemam NM, et al. Front Endocrinol (Lausanne). 2024 May 30;15:1396192. doi: 10.3389/fendo.2024.1396192. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 38872970 Free PMC article. Review.
• In Silico Evaluation of HN-N07 Small Molecule as an Inhibitor of Angiogenesis and Lymphangiogenesis Oncogenic Signatures in Non-Small Cell Lung Cancer.
  Chen LC, Mokgautsi N, Kuo YC, Wu ATH, Huang HS. Chen LC, et al. Biomedicines. 2023 Jul 17;11(7):2011. doi: 10.3390/biomedicines11072011. Biomedicines. 2023. PMID: 37509650 Free PMC article.
• Lymphatic Tissue Bioengineering for the Treatment of Postsurgical Lymphedema.
  Sung CJ, Gupta K, Wang J, Wong AK. Sung CJ, et al. Bioengineering (Basel). 2022 Apr 6;9(4):162. doi: 10.3390/bioengineering9040162. Bioengineering (Basel). 2022. PMID: 35447722 Free PMC article. Review.
• MAZ51 Blocks the Tumor Growth of Prostate Cancer by Inhibiting Vascular Endothelial Growth Factor Receptor 3.
  Yamamura A, Nayeem MJ, Muramatsu H, Nakamura K, Sato M. Yamamura A, et al. Front Pharmacol. 2021 Apr 20;12:667474. doi: 10.3389/fphar.2021.667474. eCollection 2021. Front Pharmacol. 2021. PMID: 33959030 Free PMC article.
• The Role of VEGF Receptors as Molecular Target in Nuclear Medicine for Cancer Diagnosis and Combination Therapy.
  Masłowska K, Halik PK, Tymecka D, Misicka A, Gniazdowska E. Masłowska K, et al. Cancers (Basel). 2021 Mar 3;13(5):1072. doi: 10.3390/cancers13051072. Cancers (Basel). 2021. PMID: 33802353 Free PMC article. Review.

References

1. 1. Proc Natl Acad Sci U S A. 1998 Jan 20;95(2):548-53 - PubMed
2. 1. Dev Biol. 1997 Aug 1;188(1):96-109 - PubMed
3. 1. Science. 1997 May 30;276(5317):1423-5 - PubMed
4. 1. Endocr Rev. 1997 Feb;18(1):4-25 - PubMed
5. 1. Am J Surg Pathol. 1996 Mar;20(3):286-92 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • Nature Publishing Group
  • PubMed Central

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Miscellaneous

  • NCI CPTAC Assay Portal